Notably, the J&J sent a dose from Europe to the U.S. before sending it to the joint government. Officials were sending parts to the “fill and finish” facility. According to a person familiar with the process, the company is also waiting for the Food and Drug Administration to authorize two major American partners, Emergency Bio Solutions and Catalant, which, according to a person familiar with the process, will send “millions” of usable shots. The authorization is expected to be completed in the near future, said a source familiar with the matter, adding that the number of doses issued is believed to be “in the millions”. Will be in
A senior Biden official said the administration did not expect the full shipment of the કરોડ 200 million dose to be significantly delayed. But any delay is likely to create tensions between the administration and Jammu and J, who have been accusing each other for weeks of creating unnecessary logjams in the rollout.
Emergent has been working on the production of the A&J vaccine since the beginning of last year, and said in a statement that it plans to make 1 billion vaccines this year for other vaccination partners J&J and AstraZeneca. But Emergency was not included in J & J’s original Emergency Use application, and their dosage was not used.
The situation has left administration officials frustrated as they have been told by President Biden that the U.S. Adults were instructed to be vaccinated by May.
“J&J and JJ have sluggishness in completing the material,” said a person familiar with the process. “They are slow to address some of this stuff. No one thinks they move fast. ”
When the FDA approved the use of the vaccine in late February after the company left behind its production schedule, there were approximately 4 million doses of J-Jenny single-shot vaccine available. But last month, the company told Congress it would withdraw from the U.S. by the end of March. Delivers 200 million doses to the government.
Biden administration officials hastened the return of the country to normalcy on the original single dose J&J shot, in the hope that it would dramatically accelerate the efforts to vaccinate millions of Americans. As of Monday, the company’s 3.3 million vaccines have been delivered to states, retail pharmacies, community health centers and federal vaccination sites, the CDC said.
The White House has commented on whether J&J will fulfill its 20 million shot commitment. Andy Slavitt, a senior adviser to the White House Covid team, said Monday that there would be “nice growth” in the one-shot vaccine this week.
“We’re working very closely with them,” Slavitt said. “I’m not going to signal to you that they’re going to be too far from the numbers they’re estimating – give or take a little – and it’s clear we’ll hold them accountable and work with them.”
Earlier this month, the White House instructed states to open up eligibility for vaccination to all adults by May 1 and pointed out how the country could return to some normal activities by July 4, but that targets could only increase dramatically. . Shot.
White House officials have told governors to expect about 4 to 6 million J&J shots next week, according to a source and notes from last week’s call between administrative officials and governors. Multiple states have told Politico that they are taking some J&K vaccines this week, but there is no forecast yet for individual allocations next week. The Biden administration has demanded that states give a three-week window on the number of doses they will receive.
In an effort to boost J&J supply, pharmaceutical giant Merck will help create a J&K coronavirus vaccine. The Biden administration announced it had breached the deal earlier this month, after which J&J was unable to fulfill its original promise to provide 12 million doses of its vaccine by the end of February.
